The Adult Brain Consortium (ABTC) 1501 trial is a phase I multicenter, multi-arm dose-finding study of anti-LAG (BMS-986016) or anti-CD137 (BMS-663513) alone or in combination with anti-PD1 treatment in patients at first GBM recurrence showing a manageable toxicity profile [191]. Here, TNFRSF9 is linked to glioblastoma.